+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032- Product Image
Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032- Product Image
Sale

Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126931
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptide-Radionuclide Conjugates Market is projected to reach USD 1.13 Billion in 2026. It is expected to continue growing at a CAGR of 17.22%, reaching USD 2.95 Billion by 2032.

Peptide-Radionuclide Conjugates: Executive Summary

Peptide-radionuclide conjugates combine tumor-targeting peptides with therapeutic or diagnostic radionuclides. Their development is shaped by advances in molecular targeting, radiochemistry, nuclear medicine, imaging, and oncology care. The field remains clinically specialized, requiring coordinated evidence across safety, dosimetry, patient selection, manufacturing, and radiation handling.

Clinical Translation Is Reshaping the Radiopharmaceutical Landscape

The landscape is shifting from exploratory radioligand research toward more integrated theranostic pathways, in which imaging helps identify target expression and treatment suitability. Progress depends on reliable peptide production, radionuclide availability, conjugation chemistry, validated imaging protocols, and clinical workflows capable of managing radiation exposure. Regulatory expectations increasingly emphasize product consistency, pharmacokinetics, dosimetry, and clinically meaningful outcomes.

Artificial Intelligence Strengthens Targeting, Development, and Care Pathways

Artificial intelligence can support peptide discovery, molecular-property prediction, image interpretation, lesion segmentation, treatment-response assessment, and individualized dosimetry. Its value is greatest when models are trained on clinically representative, quality-controlled data and integrated with expert review. Adoption remains constrained by limited datasets, inconsistent imaging protocols, explainability requirements, cybersecurity concerns, and the need for prospective clinical validation.

Regional Insights: Uneven Infrastructure Defines Adoption Conditions

North America benefits from established oncology research, nuclear-medicine expertise, and advanced imaging infrastructure, while Latin America faces greater variability in isotope access, specialized facilities, and reimbursement pathways. Europe has strong radiopharmaceutical research capabilities and a coordinated regulatory environment, although cross-border production and distribution remain operationally complex. The Middle East is expanding precision-medicine capacity in selected centers, whereas Africa continues to experience shortages of nuclear-medicine infrastructure and trained personnel. Asia-Pacific combines substantial clinical and manufacturing capabilities in several economies with uneven access across emerging healthcare systems.

Group Insights: Cooperation and Supply Resilience Are Central

ASEAN countries show differing levels of nuclear-medicine infrastructure and regulatory maturity, making regional collaboration important. BRICS members span major research, manufacturing, and clinical capabilities but face varied access to isotopes, capital, and specialized expertise. The European Union benefits from regulatory coordination and cross-border research networks, while the G7 provides a strong base of advanced clinical, pharmaceutical, and imaging capabilities. GCC countries are investing in specialized healthcare infrastructure, and NATO members collectively contribute substantial research and security expertise relevant to resilient medical-isotope supply chains.

Country Insights: Capabilities Range from Mature Programs to Emerging Capacity

The United States and Canada have advanced oncology and nuclear-medicine ecosystems, while the United Kingdom, France, Germany, Italy, and Spain contribute established European clinical, regulatory, and research capabilities. Australia supports specialized nuclear-medicine research across a geographically dispersed system. China, Japan, and South Korea possess significant capabilities in radiopharmaceutical development, imaging, and precision oncology, with Japan also benefiting from extensive nuclear-medicine experience. India is expanding research and manufacturing capacity, while Brazil and Mexico are developing specialized services amid infrastructure and access constraints. Russia retains nuclear and radiopharmaceutical expertise, although international collaboration and supply-chain conditions affect development pathways.

Action Priorities for Industry Leaders

Leaders should build integrated development plans linking target validation, peptide engineering, radionuclide selection, dosimetry, imaging, and clinical endpoints. They should secure diversified isotope and precursor supply, qualify scalable manufacturing processes, and establish robust quality systems early. Partnerships with treatment centers can improve patient-selection protocols and real-world evidence, while workforce investment is essential for radiochemistry, medical physics, radiation safety, and nuclear-medicine operations. Responsible AI deployment should use governed datasets, transparent validation, human oversight, and continuous performance monitoring.

Research Methodology: Evidence-Led Market Assessment

This executive summary synthesizes the supplied market scope with established scientific and healthcare-sector evidence concerning peptide targeting, radionuclide therapy, diagnostic imaging, radiopharmaceutical manufacturing, regulation, and clinical infrastructure. Insights are organized by technology, geography, economic grouping, and country. No market estimates, market shares, forecasts, or company-specific claims are included; conclusions are limited to documented structural, clinical, operational, and policy considerations.

Conclusion: Execution Will Determine Clinical and Regional Progress

Peptide-radionuclide conjugates sit at the intersection of precision oncology, molecular imaging, and advanced pharmaceutical manufacturing. Progress will depend less on a single technical advance than on coordinated improvement across target biology, isotope resilience, quality control, dosimetry, clinical workflow, reimbursement, and specialist training. Organizations that connect these elements while validating AI and maintaining rigorous safety standards will be best positioned to support responsible clinical adoption across diverse healthcare systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Peptide-Radionuclide Conjugates Market, by Radionuclide Type
7.1. Introduction
7.2. Actinium-225
7.3. Lutetium-177
7.4. Yttrium-90
8. Peptide-Radionuclide Conjugates Market, by Therapeutic Indication
8.1. Introduction
8.2. Bone Metastases
8.3. Neuroendocrine Tumors
8.4. Prostate Cancer
9. Peptide-Radionuclide Conjugates Market, by Route Administration
9.1. Introduction
9.2. Intratumoral
9.3. Intravenous
10. Peptide-Radionuclide Conjugates Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. General Hospitals
10.2.2. Specialized Cancer Centers
10.3. Oncology Centers
10.3.1. Academic Centers
10.3.2. Private Clinics
10.4. Research Institutes
11. Peptide-Radionuclide Conjugates Market, by Distribution Channel
11.1. Introduction
11.2. Direct Purchase
11.2.1. InHouse Radiopharmacy
11.2.2. Onsite Pharmacy
11.3. Direct Tender
11.4. Distributors
12. Peptide-Radionuclide Conjugates Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Peptide-Radionuclide Conjugates Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Peptide-Radionuclide Conjugates Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Angiochem Inc.
16.2. Ariceum Therapeutics
16.3. AstraZeneca PLC
16.4. Bayer AG
16.5. Bicycle Therapeutics Ltd.
16.6. Bristol Myers Squibb Company
16.7. Curium Pharma
16.8. Cybrexa Therapeutics Inc.
16.9. Eli Lilly and Company
16.10. Genentech, Inc.
16.11. ITM Isotope Technologies Munich SE
16.12. NorthStar Medical Radioisotopes LLC
16.13. Novartis AG
16.14. PeptiDream Inc.
16.15. Telix Pharmaceuticals Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Peptide-Radionuclide Conjugates Market, Years Considered for the Study
FIGURE 2. Global Peptide-Radionuclide Conjugates Market, Research Design
FIGURE 3. Global Peptide-Radionuclide Conjugates Market, Research Framework
FIGURE 4. Global Peptide-Radionuclide Conjugates Market, Data Triangulation
FIGURE 5. Global Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2025 vs 2032 (%)
FIGURE 7. Global Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2025 vs 2032 (%)
FIGURE 9. Global Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2025 vs 2032 (%)
FIGURE 11. Global Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Peptide-Radionuclide Conjugates Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Peptide-Radionuclide Conjugates Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Peptide-Radionuclide Conjugates Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Peptide-Radionuclide Conjugates Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Peptide-Radionuclide Conjugates Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Peptide-Radionuclide Conjugates Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Peptide-Radionuclide Conjugates Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Peptide-Radionuclide Conjugates Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Peptide-Radionuclide Conjugates Market Segmentation & Coverage
TABLE 2. Global Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 3. Global Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 4. Global Actinium-225 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Actinium-225 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Actinium-225 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Lutetium-177 Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Lutetium-177 Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Lutetium-177 Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Yttrium-90 Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Yttrium-90 Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Yttrium-90 Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 14. Global Bone Metastases Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Bone Metastases Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Bone Metastases Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Neuroendocrine Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Neuroendocrine Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Neuroendocrine Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 24. Global Intratumoral Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Intratumoral Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Intratumoral Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 31. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global General Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global General Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global General Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Specialized Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Specialized Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Specialized Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Oncology Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Oncology Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Oncology Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Academic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Academic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Academic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Private Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Private Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Private Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 53. Global Direct Purchase Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Direct Purchase Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Direct Purchase Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global InHouse Radiopharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global InHouse Radiopharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global InHouse Radiopharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Onsite Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Onsite Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Onsite Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Direct Tender Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Direct Tender Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Direct Tender Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Distributors Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Distributors Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Distributors Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 78. North America Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. North America Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 80. North America Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 81. North America Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 82. North America Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. North America Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 84. North America Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 85. North America Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. North America Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 87. Latin America Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Latin America Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 89. Latin America Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 90. Latin America Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 91. Latin America Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Latin America Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 93. Latin America Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 94. Latin America Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Latin America Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 96. Europe Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Europe Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 98. Europe Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 99. Europe Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 100. Europe Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Europe Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 102. Europe Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 103. Europe Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Europe Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 105. Middle East Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Middle East Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 107. Middle East Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 108. Middle East Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 109. Middle East Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Middle East Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 111. Middle East Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 112. Middle East Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Middle East Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 114. Africa Peptide-Radionuclide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Africa Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 116. Africa Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 117. Africa Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 118. Africa Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Africa Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 120. Africa Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 121. Africa Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Africa Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 123. Global Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. ASEAN Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. ASEAN Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 126. ASEAN Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 127. ASEAN Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 128. ASEAN Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. ASEAN Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 130. ASEAN Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 131. ASEAN Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. ASEAN Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 133. GCC Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. GCC Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 135. GCC Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 136. GCC Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 137. GCC Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. GCC Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 139. GCC Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 140. GCC Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. GCC Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 142. European Union Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. European Union Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 144. European Union Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 145. European Union Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 146. European Union Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. European Union Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 148. European Union Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 149. European Union Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. European Union Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 151. BRICS Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. BRICS Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 153. BRICS Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 154. BRICS Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 155. BRICS Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. BRICS Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 157. BRICS Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 158. BRICS Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. BRICS Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 160. G7 Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. G7 Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 162. G7 Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 163. G7 Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 164. G7 Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. G7 Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 166. G7 Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 167. G7 Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. G7 Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 169. NATO Peptide-Radionuclide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. NATO Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 171. NATO Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 172. NATO Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 173. NATO Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. NATO Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 175. NATO Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 176. NATO Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. NATO Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 178. Global Peptide-Radionuclide Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. United States Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 180. United States Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 181. United States Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 182. United States Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 183. United States Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. United States Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 185. United States Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 186. United States Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. United States Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 188. Canada Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 189. Canada Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 190. Canada Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 191. Canada Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 192. Canada Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Canada Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 194. Canada Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 195. Canada Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Canada Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 197. Mexico Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 198. Mexico Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 199. Mexico Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 200. Mexico Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 201. Mexico Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Mexico Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 203. Mexico Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 204. Mexico Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Mexico Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 206. Brazil Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 207. Brazil Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 208. Brazil Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 209. Brazil Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 210. Brazil Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Brazil Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 212. Brazil Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 213. Brazil Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. Brazil Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 215. United Kingdom Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 216. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 217. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 218. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 219. United Kingdom Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 221. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 222. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. United Kingdom Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 224. Germany Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 225. Germany Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 226. Germany Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 227. Germany Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 228. Germany Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Germany Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 230. Germany Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 231. Germany Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Germany Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 233. France Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 234. France Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 235. France Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 236. France Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 237. France Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. France Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 239. France Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 240. France Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. France Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 242. Russia Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 243. Russia Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 244. Russia Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 245. Russia Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 246. Russia Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. Russia Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 248. Russia Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 249. Russia Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. Russia Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 251. Italy Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 252. Italy Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 253. Italy Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 254. Italy Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 255. Italy Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Italy Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 257. Italy Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 258. Italy Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Italy Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 260. Spain Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 261. Spain Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 262. Spain Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 263. Spain Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 264. Spain Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. Spain Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 266. Spain Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 267. Spain Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Spain Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 269. China Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 270. China Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 271. China Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 272. China Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 273. China Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. China Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 275. China Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 276. China Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. China Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 278. India Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 279. India Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 280. India Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 281. India Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 282. India Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. India Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 284. India Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 285. India Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. India Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 287. Japan Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 288. Japan Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 289. Japan Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 290. Japan Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 291. Japan Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. Japan Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 293. Japan Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 294. Japan Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. Japan Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 296. Australia Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 297. Australia Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 298. Australia Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 299. Australia Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 300. Australia Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Australia Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 302. Australia Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 303. Australia Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 304. Australia Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 305. South Korea Peptide-Radionuclide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 306. South Korea Peptide-Radionuclide Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 307. South Korea Peptide-Radionuclide Conjugates Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 308. South Korea Peptide-Radionuclide Conjugates Market Size, by Route Administration, 2017-2032 (USD Million)
TABLE 309. South Korea Peptide-Radionuclide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. South Korea Peptide-Radionuclide Conjugates Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 311. South Korea Peptide-Radionuclide Conjugates Market Size, by Oncology Centers, 2017-2032 (USD Million)
TABLE 312. South Korea Peptide-Radionuclide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. South Korea Peptide-Radionuclide Conjugates Market Size, by Direct Purchase, 2017-2032 (USD Million)
TABLE 314. Global Peptide-Radionuclide Conjugates Market Share, by Key Player, 2025
TABLE 315. Global Peptide-Radionuclide Conjugates Market, Key Experts

Companies Mentioned

  • Angiochem Inc.
  • Ariceum Therapeutics
  • AstraZeneca PLC
  • Bayer AG
  • Bicycle Therapeutics Ltd.
  • Bristol Myers Squibb Company
  • Curium Pharma
  • Cybrexa Therapeutics Inc.
  • Eli Lilly and Company
  • Genentech, Inc.
  • ITM Isotope Technologies Munich SE
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • PeptiDream Inc.
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032 - Product Image

Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Peptide Receptor Radionuclide Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Peptide Receptor Radionuclide Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2026-2034 - Product Image

Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2026-2034

  • Report
  • 145 Pages
  • Global
From
Cancer & Antibody Conjugates Patent Landscape Analysis 2025 - Product Image

Cancer & Antibody Conjugates Patent Landscape Analysis 2025

  • Report
  • 100 Pages +
  • Global
Peptide Antibody Conjugate Market - Global Forecast 2026-2032 - Product Image

Peptide Antibody Conjugate Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.